Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

– Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 – Ended the quarter with $12.6 million in cash allowing funding for planned pipeline development EDMONTON, Alberta, May ... | May 25, 2023

Related Keywords

China ,Montreal ,Quebec ,Canada ,United States ,Canadian ,Chinese ,Beta Glucan ,Jenene Thomas ,Gillesr Gagnon ,Gilles Gagnon ,Corporate Communications Advisor ,Pipeline Development ,Clinical Development ,Angiogenesis Foundation ,Venture Exchange ,Montreal Heart Institute ,Mcmaster University ,Ceapro Inc ,Expanded Technology ,First In Human Study ,Assess Safety ,Multiple Ascending Oral ,Montreal Heart ,Agri Food Discovery Place ,Michel Regnier ,Senior Vice President ,Operations Executive ,Professional Engineer ,First Quarter Ended March ,Interim Consolidated Statements ,Months Ended March ,Corporate Communications ,Ceapro Inc Stock Exchange ,News ,Information ,Press Release ,1 ,023 ,Sales ,F ,Us ,N ,022 ,Nded ,The ,Quarter ,Ith ,Cash ,Following ,Funding ,Or ,Planned ,Ay Czo Ca1499071076 ,